GENFLOW BIOSCIENCES PLC (F:WQ5) — Market Cap & Net Worth
Market Cap & Net Worth: GENFLOW BIOSCIENCES PLC (WQ5)
GENFLOW BIOSCIENCES PLC (F:WQ5) has a market capitalization of $13.15 Million (€11.25 Million) as of July 22, 2026. Listed on the F stock exchange, this Germany-based company holds position #26371 globally and #2264 in its home market, demonstrating a -4.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENFLOW BIOSCIENCES PLC's stock price €0.02 by its total outstanding shares 535653205 (535.65 Million). Review WQ5 liabilities breakdown to assess the company's total debt and financial obligations.
GENFLOW BIOSCIENCES PLC Market Cap History: 2022 to 2026
GENFLOW BIOSCIENCES PLC's market capitalization history from 2022 to 2026. Data shows change from $16.28 Million to $13.15 Million (-34.36% CAGR).
GENFLOW BIOSCIENCES PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENFLOW BIOSCIENCES PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of WQ5 by Market Capitalization
Companies near GENFLOW BIOSCIENCES PLC in the global market cap rankings as of July 22, 2026.
Key companies related to GENFLOW BIOSCIENCES PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #560 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $480.50 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $672.15 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €753.60 |
| #560 | UCB SA | BR:UCB | $47.34 Billion | €238.00 |
GENFLOW BIOSCIENCES PLC Historical Marketcap From 2022 to 2026
Between 2022 and today, GENFLOW BIOSCIENCES PLC's market cap moved from $16.28 Million to $ 13.15 Million, with a yearly change of -34.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.15 Million | +10.53% |
| 2025 | €11.90 Million | -2.56% |
| 2024 | €12.21 Million | +25.81% |
| 2023 | €9.71 Million | -40.38% |
| 2022 | €16.28 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of GENFLOW BIOSCIENCES PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.15 Million USD |
| MoneyControl | $13.15 Million USD |
| MarketWatch | $13.15 Million USD |
| marketcap.company | $13.15 Million USD |
| Reuters | $13.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENFLOW BIOSCIENCES PLC
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducin… Read more